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Abstract  24 
This study aimed to determine the impact of fat intake combined with Bacillus coagulans or 25 
trans-galactooligosaccharides (B-GOS) on bacterial composition and immune markers in an in 26 
vitro model. A three-stage continuous gut model system was used to simulate specific human 27 
colonic regions. Peripheral blood mononuclear cells were exposed to cell free supernatants and 28 
subsequent levels of inflammatory cytokines were measured by flow cytometry. Although fat 29 
addition decreased bifidobacteria from 8.76±0.12 to 8.63±0.13 and from 8.83±0.08 to 30 
8.67±0.07 in pre- and probiotic models respectively, the changes were not significant. Fat 31 
addition also did not impact on cytokines induced by LPS. Under high fat conditions, numbers 32 
of bifidobacteria significantly increased by B. coagulans or B-GOS. In addition, B. coagulans 33 
or B-GOS significantly suppressed TNF-αproduction induced by LPS. Under high fat 34 
conditions, either B. coagulans or B-GOS led to potentially beneficial effects by targeting 35 
specific bacterial groups and modulating immune markers. 36 
Abbreviations 37 
B-GOS, trans-galactooligosaccharides; IL-6, interleukin-6; IL-1β, interleukin-1β; TNF-α,  38 
tumour necrosis factor-α; NK, natural killer; FISH, fluorescent in situ hybridisation; SS, steady 39 
state; SCFA, short-chain fatty acid; GC, gas chromatography; PBMCs, peripheral blood 40 
mononuclear cells; LPS, lipopolysaccharide 41 
Keywords 42 
Probiotics; Prebiotics; Fat; Microbiota; Immune markers 43 
 44 
3 
 
Chemical compounds studied in this article 45 
Galactooligosaccharides (PubChem CID: 165512). 46 
1. Introduction 47 
It has been reported that between the years 2000 and 2050, the percentage of the population 48 
aged 60 and over is likely to double from about 11% to 22% (WHO, 2014). Subsequently, 49 
requirements for long-term care, including home nursing, are increasing. Compared to young 50 
adults, elderly people suffer from some physical and functional changes. For example, poor 51 
chewing and swallowing (Castell, 1988; Karlsson, Persson, & Carlsson, 1991; Remond et al., 52 
2015) can result in reduced dietary choice, poor nutrition, digestion and absorption (Remond 53 
et al., 2015). In terms of effects on the gastrointestinal tract, Woodmansey, McMurdo, 54 
Macfarlane, and Macfarlane (2004) suggested that less gastrointestinal mobility and longer 55 
transit time might result in a higher susceptibility to colon disorders.  56 
In addition, elderly populations typically have increased levels of cytokines associated with 57 
inflammation such as interleukin-6 (IL-6), IL-1β, and tumour necrosis factor-α (TNF-α), along 58 
with decreased phagocytosis and natural killer (NK) cell activity. These immunological 59 
changes are loosely termed immunosenescence (Bruunsgaard, Pedersen, Schroll, Skinhoj, & 60 
Pedersen, 2001; Butcher et al., 2001; Goodwin, 1995; Schiffrin, Morley, Donnet-Hughes, & 61 
Guigoz, 2010; Vulevic, Drakoularakou, Yaqoob, Tzortzis, & Gibson, 2008). 62 
The combination of age-related changes in the gastrointestinal tract, such as decreased transit 63 
time and increased mucosal membrane permeability (Hopkins, Sharp, & Macfarlane, 2002), 64 
dietary changes on the microbiota (Candela, Biagi, Turroni, Rampelli, & Brigidi, 2015; 65 
Rampelli et al., 2013a; Rampelli et al., 2016; Vulevic et al., 2008). Indeed, studies have shown 66 
decreased viable counts of Bacteroides in elderly compared to younger adults (Hopkins & 67 
Macfarlane, 2002; Woodmansey et al., 2004). A reduction of bifidobacteria in numbers and 68 
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species diversity is one of the most notable changes in elderly populations and has been 69 
reported in studies using traditional culture methods as well as molecular methods (Claesson 70 
et al., 2011; Gavini et al., 2001; Hopkins & Macfarlane, 2002; Hopkins, Sharp, & Macfarlane, 71 
2001; Mitsuoka, 1992; Mueller et al., 2006; Woodmansey et al., 2004). In addition, the age-72 
related microbiota changes in elderly were associated with decreased short-chain fatty acid 73 
(SCFA) production, 90-95% of which are acetate, propionate, and butyrate and originate from 74 
fermentation of non-digestible carbohydrates (Puddu, Sanguineti, Montecucco, & Viviani, 75 
2014). Elderly individuals were characterised with decreased saccharolytic fermentation and 76 
increased proteolytic fermentation compared to younger adults (Rampelli et al., 2013c). These 77 
age-related changes in microbiota composition may drive some of the immune response 78 
changes and could lead to higher disease risk in elderly compared to younger adults. 79 
According to a recent report (Bates, Lennox, Prentice, Bates, & Swan, 2012), a typical elderly 80 
person’s daily intake of total fat is 36.1% food energy of which 14.2% is saturated fatty acids, 81 
these are higher than the UK Dietary Reference Values, of 35% and 11% respectively. In murine 82 
studies, a high fat diet has been shown to have negative effects on microbiota composition, 83 
including, for example lower Bacteroides group and higher Firmicutes phylum in animal 84 
models (Cani et al., 2007a; Cani et al., 2007i; Pyndt Jørgensen et al., 2014; Rampelli et al., 85 
2016). A high fat diet may also impact upon Clostridium spp. and Lactobacillus spp., which 86 
have been observed to decrease following high fat treatments (Biagi et al., 2010; Cani et al., 87 
2007a; Druart et al., 2013). High fat diets are also associated with a negative impact on immune 88 
function in murine studies. For example, increased levels of TNF-α, IL-1β and IL-6 in plasma 89 
and tissues following a high fat diet have been observed in animal models, subsequently 90 
resulting in greater inflammatory status (Cani et al., 2007a; Cani et al., 2007i; Chen, Wang, Li, 91 
& Wang, 2011; Kim, Gu, Lee, Joh, & Kim, 2012; Lam et al., 2012; Neyrinck et al., 2011; Park 92 
et al., 2013). Because elderly people are consuming high fat diets, they may additionally be 93 
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more vulnerable to disease risk. Therefore, the impact of high fat consumption on elderly 94 
persons may be relevant. 95 
Several murine studies have shown that prebiotics and probiotics can positively modulate the 96 
gut microbial composition and immune markers following a high fat diet (Cani et al., 2007i; 97 
Chen et al., 2011; Park et al., 2013). Trans-galactooligosaccharides (B-GOS) are promising 98 
prebiotics that have been observed to positively improve microbiota composition and immune 99 
function in the elderly (Vulevic et al., 2008; Vulevic et al., 2015). The impact of B-GOS 100 
following a high fat diet has not been investigated. However, B-GOS was shown to increase 101 
the number of faecal bifidobacteria and decrease C. histolyticum group in overweight adults 102 
(Vulevic, Juric, Tzortzis, & Gibson, 2013). B-GOS may have promising potential to modulate 103 
microbiota composition and immune markers in elderly under high fat intakes. Bacillus 104 
coagulans GBI-30, 6086 (GanedenBC30 (BC30)) has the potential to suppress the growth of 105 
pathogens (Honda, Gibson, Farmer, Keller, & McCartney, 2011). B. coagulans can also 106 
modulate the microbiota with significant increases observed in Bacillus spp., C. litsueburense 107 
and F. prausnitzii after 28-day supplementation in healthy elderly adults (65 and 80 years) 108 
(Nyangale, Farmer, Keller, Chernoff, & Gibson, 2014). In an in vitro study, both the cell wall 109 
and metabolite fractions of B. coagulans induced IL-10 production, thereby demonstrating anti-110 
inflammatory potential. This suggests immune modulating effects of BC30 B. coagulans 111 
(Jensen, Benson, Carter, & Endres, 2010) which could help to combat both ageing and high-112 
fat diet effects. In addition, the safety of Bacillus coagulans GBI-30, 6086 has been confirmed 113 
including exerting no mutagenic, clastogenic or genotoxic effects (Endres et al., 2009), 114 
harbouring no risk-associated genes and producing no biogenic amine (Salvetti et al., 2016). 115 
Recent studies have provided a good indication about prebiotic and probiotic effects on elderly 116 
populations. However, the influence of prebiotic and probiotic (B-GOS and B. coagulans) on 117 
elderly persons in the presence of high fats has not been well studied. Therefore, the aim of the 118 
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current study was to assess the impact of B. coagulans and B-GOS on bacterial composition 119 
and immune markers in senior individuals consuming a high fat diet using a three-stage gut 120 
model. 121 
2. Materials and methods 122 
2.1. Chemicals and bacteria 123 
Unsalted butter (Sainsbury's basics, UK), sunflower oil (Sainsbury's SO Organic, UK) and 124 
olive oil (Filippo Berio, UK) were from Sainsbury's supermarket (Reading, UK). Coconut oil 125 
was from Holland and Barrett (Reading, UK). B-GOS mixture was from Clasado Ltd (Milton 126 
Keynes, UK), the degree of polymerisation ranged from 2 to 5, average molecular weight was 127 
496.8 kDa, and galactooligosaccharide content of B-GOS mixture was 58% (w/w). Bacillus 128 
coagulans: GBI-30 (PTA-6086, GanedeBC30TM) was sourced from American Type Culture 129 
Collection (Manassas, United States) and was used as spores in the current study. All nucleotide 130 
probes used for fluorescent in situ hybridisation (FISH) were commercially synthesised and 131 
labelled with the fluorescent dye Cy3 at the 5′ end (Sigma Aldrich Co. Ltd., Spain). Sterilisation 132 
of media and instruments was done by autoclaving at 121 °C for 15 min. 133 
2.2. Three-stage continuous culture system 134 
The physicochemical conditions in the colon were replicated in the three-stage continuous 135 
system, as validated by Macfarlane, Macfarlane, and Gibson (1998). It was set up simulating, 136 
the proximal, transverse and distal colon, which were present as three connected fermentation 137 
vessels (V1, V2, and V3). Faecal samples were donated by three healthy persons aged over 60 138 
years old (2 female and 1 male). Volunteers were not regular consumers of pre or probiotics 139 
and had not received antibiotic treatment in the previous three months. A different faecal donor 140 
was used for each of the three repetitions. A 20% (w/v) faecal slurry (28.57ml (V1), 33.33 ml 141 
(V2), 37.5 ml (V3)) was inoculated into culture medium (51.43 ml (V1), 66.67 ml (V2), 82.5 142 
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ml (V3)) and left to equilibrate for 24 hours as a batch culture system. Briefly, culture medium 143 
was prepared in distilled water and consisted of (litre-1): 5g starch, 5g peptone water, 5g 144 
tryptone, 4.5g yeast extract, 4.5g NaCl, 4.5g KCl, 4g mucin (porcine gastric type III), 3g casein, 145 
2g pectin (citrus), 2g xylan (oatspelt), 2g arabinogalactan (larch wood), 1.5g NaHCO3, 1.25g 146 
MgSO4.7H2O, 1g guar gum, 1g inulin, 0.8g cysteine, 0.5g KH2PO4, 0.5g K2HPO4, 0.4g bile 147 
salts No. 3, 0.15g CaCl2.6H2O, 0.005g FeSO4.7H2O, 0.05g hemin, 10µl Vitamin K and 1ml 148 
Tween 80. Following this, the medium flow was turned on with a system retention time of 48 149 
hours, culture temperature was 37°C and pH in each vessel was 5.5 (V1), 6.2 (V2), 6.8 (V3), 150 
these were maintained using a pH pump (Electrolab, UK) with 0.5M NaOH and HCl solutions 151 
as appropriate. An anaerobic environment was maintained by continuous sparging of oxygen-152 
free nitrogen supply (15 mL/min). 153 
During in vitro fermentation, the initial steady state (SS1), when equilibrium was reached, was 154 
at day 16. This was confirmed by stabilisation of SCFA profiles after three consecutive days. 155 
Following SS1, high fat mixture (4.78g), (unsalted butter 2g, coconut oil 0.83g, sunflower oil 156 
1.17g and olive oil 1.33g) was added into vessel 1 daily (Table 1). A second steady state (SS2) 157 
was reached after 35 days. SS3 involved daily addition of the same amount of fat mixture as 158 
SS2 and either probiotic (B. coagulans) or prebiotic B-GOS mixture treatment until equilibrium 159 
at 53 days. B. coagulans (GanedenBC30) was added into V1 at a dose of 3.3×108 cfu daily 160 
(Table 1). Another 3 gut systems were fed 2.5g of B-GOS mixture in V1 daily. This B-GOS 161 
mixture consisted of the following ingredients: glucose 0.394g; galactose 0.017g; lactose 162 
0.348g; B-GOS 1.063g; protein 0.003g; ash 0.008g and moisture 0.611g, in which the B-GOS 163 
content of B-GOS mixture was 58% (w/w). The same amounts of glucose, galactose and 164 
lactose were also added to non-prebiotic fed gut models daily (Table 1). Samples (5ml) were 165 
collected from each vessel at each steady state over three consecutive days for further analysis. 166 
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2.3. Sample preparation 167 
A sample of 375µl (in duplicate) was taken for FISH analysis. This sample was fixed 168 
immediately in 4% (w/v) paraformaldehyde solution (1125µl) at 4°C for 4 hours, then 169 
centrifuged for 5 minutes at 11337 g (Eppendorf centrifuge minispin, Eppendorf, UK) at room 170 
temperature. The supernatant was carefully removed and discarded. The pellet was re-171 
suspended in 1 ml of cold 1×PBS by aspirating carefully using a pipette. Again, the sample 172 
was centrifuged for 5 minutes at 11337 g at room temperature and the supernatant discarded. 173 
The sample was washed again in 1 ml cold PBS as above and centrifuged. All supernatant was 174 
carefully removed. Finally, the pellet was re-suspended in 150 µl cold 1×PBS and 150 µl 175 
ethanol. The sample was mixed by vortexing and then stored at -20°C, for FISH based analysis 176 
of bacterial counts.  177 
In preparation for SCFA analysis, 1 ml duplicate samples were taken and centrifuged (11337 g, 178 
10 min) at room temperature. The supernatant was stored at -20°C for future analysis. 179 
In preparation for in vitro immunoassays, 1 ml of gut model supernatant was sampled in 180 
triplicate, centrifuged for 10 minutes at 11337 g at room temperature and then filtered through 181 
a 0.22 µm filter device (Millipore, Schwalbach, Germany). The cell-free supernatant was stored 182 
at -20°C. 183 
2.4. Bacterial enumeration 184 
FISH analysis involved the use of fluorescently labelled oligonucleotide probes (using Cy3), 185 
targeting specific 16S rRNA sequences (Daims, Stoecker, & Wagner, 2005). The probes used 186 
in this study were: Ato 291 for Atopobium cluster (Atopobium, Coriobacterium, Collinsella 187 
spp.) (Harmsen et al., 2000), Lab 158 for lactobacilli/enterococci (Harmsen, Elfferich, Schut, 188 
& Welling, 1999), Bif 164 for bifidobacteria (Langendijk et al., 1995), Erec 482 for 189 
Eubacterium rectale – Clostridium coccoides group (Franks et al., 1998), Chis 150 for the 190 
Clostridium histolyticum group (Franks et al., 1998), Bcoa 191 for Bacillus spp. (Sakai & Ezaki, 191 
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2006), Bac 303 for Bacteroides–Prevotella spp. (Manz, Amann, Ludwig, Vancanneyt, & 192 
Schleifer, 1996), and EUB 338 mixture consisting of EUB338, EUB338II and EUB338III for 193 
total bacteria (Daims, Bruhl, Amann, Schleifer, & Wagner, 1999). Conditions of hybridisation 194 
and washing for individual probes are given in Supplementary 1. Hybridisation of samples was 195 
performed as described by Daims et al. (2005).  196 
Briefly, fixed samples were kept on ice and diluted with PBS solution, then 20 μl diluted 197 
suspension was evenly placed onto a 5mm diameter well in Teflon- and poly L-lysine-coated 198 
slide (Tekdon Inc, Myakka City, FL). These slides were dried for 15 min at 46-50°C and 199 
washed in 50%, 80% and 96% (v/v) ethanol solution for 3 minutes respectively, then dried for 200 
2 min. Some Gram-positive bacteria needed lysozyme treatment prior to hybridisation, such as 201 
bifidobacteria and lactobacilli/enterococci. 20 μl of lysozyme (1 mg/ml) was therefore added 202 
to each well before dehydration in ethanol. Following this, 50μl pre-warmed hybridisation 203 
buffer (0.9 M NaCl, 0.02 M Tris/HCl (pH 8.0), (Supplementary 1), 0.05μl 10 % (w/v) sodium 204 
dodecyl sulphate, 39.95μl HPLC water and 4.55 ng ml-1 probe) were added to each well, and 205 
slides placed on a tray, which was sealed and put in a hybridisation oven for 4h at probe specific 206 
hybridisation temperature (Supplementary 1). 20 µl nucleic acid stain 4’, 6-diamidino-2- 207 
phenylindole (DAPI; 50 ng µl-1) was added to the wash buffer before hybridisation finished. 208 
Once the hybridisation was complete, slides were placed into wash buffer (0.9 M NaCl, 0.02 209 
M Tris/HCl (pH 8.0), 0.005 M ethylenediaminetetraacetic acid (EDTA) solution (pH 8.0, 210 
Supplementary 1), H2O), warmed at the appropriate temperature for each probe 211 
(Supplementary 1) for 10-15 minutes. After washing, slides were dipped into ice-cold distilled 212 
water for 2-3 seconds and dried by a stream of compressed air. Finally, antifade solution (Dabco) 213 
was added to each well, a cover slip applied and slides examined using fluorescence 214 
microscopy (Nikon Eclipse E400; Nikon, Tokyo, Japan). 215 
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2.5. Organic analysis  216 
SCFAs were determined by gas chromatography (GC) following N-(tert-butyldimethylsilyl)-217 
N-methyltrifluoroacetamide derivitisation (Richardson, Calder, Stewart, & Smith, 1989). Each 218 
sample was vortexed and 1 ml of sample or a standard solution transferred into a labelled 100 219 
mm×16 mm glass tube (Fisher Scientific UK Ltd, Loughborough) with 50 μl of 2-ethylbutyric 220 
acid (0.1 M internal standard solution), 500 μl concentrated HCl and 2 ml diethyl ether. All 221 
samples were vortexed for 1 min and centrifuged at 2000 g for 10 min at room temperature 222 
(SANYO MSE Mistral 3000i, Sanyo Gallenkap PLC, UK) twice (1 ml of diethyl ether added 223 
in second extraction), aiming to completely extract the SCFAs. 400 µl of the pooled ether 224 
extract and 50 µl N-(tert-butyldimethylsilyl)-N-methyltrifluoroacetamide (MTBSTFA) were 225 
added into a GC screw-cap vial. Samples were heated at 80°C for 20 min and kept at room 226 
temperature for 48h to enable further derivatisation.  227 
A 5890 SERIES II Gas Chromatograph (Hewlett Packard, UK) using an Rtx-1 10m×0.18mm 228 
column with a 0.20μm coating (Crossbond 100% dimethyl polysiloxane; Restek, 229 
Buckinghamshire, UK) was used for SCFA analysis. Temperature of injector and detector was 230 
275°C, with the column programmed from 63°C for 3 minutes to 190°C at 10°C min-1 and held 231 
at 190°C for 3 minutes. Helium was the carrier gas (flow rate 1.2 ml min-1; head pressure 90 232 
MPa). A split ratio of 100:1 was used. The SCFA external standard was run every 20 samples 233 
to update the calibration as necessary. The SCFA external standard solution contained (mM): 234 
sodium formate, 10; acetic acid, 30; propionic acid, 20; isobutyric acid, 5; n-butyric acid, 20; 235 
iso-valeric acid, 5; n-valeric acid, 5; sodium lactate, 10; sodium succinate, 20. This standard 236 
was treated the same as the samples and derivatised with added internal standard. Peak areas 237 
of the standard solution, to which internal standard was added, were used to calculate the 238 
response factors for each organic acid with respect to the internal standard. Response factor 239 
and peak areas within samples were calibrated and calculated using Chemstation B.03.01 240 
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(Agilent Technologies, Cheshire, UK). Response factors were calculated using Equation 1. The 241 
amount of organic acids with the samples was calculated using Equation 2. 242 
 243 
𝐼𝑛𝑡𝑒𝑟𝑛𝑎𝑙 𝑅𝑒𝑠𝑝𝑜𝑛𝑠𝑒 𝐹𝑎𝑐𝑡𝑜𝑟 =
𝑎𝑟𝑒𝑎𝐼𝑆 × 𝑎𝑚𝑜𝑢𝑛𝑡𝑆𝐶
𝑎𝑚𝑜𝑢𝑛𝑡𝐼𝑆 × 𝑎𝑟𝑒𝑎𝑆𝐶
 244 
Equation 1 IS=Internal Standard; SC=Specific Compound of Interest 245 
𝐴𝑚𝑜𝑢𝑛𝑡 𝑜𝑓 𝑆𝑝𝑒𝑐𝑖𝑓𝑖𝑐 𝐶𝑜𝑚𝑝𝑜𝑢𝑛𝑑 =
𝑎𝑚𝑜𝑢𝑛𝑡𝐼𝑆 × 𝑎𝑟𝑒𝑎𝑆𝐶 × 𝐼𝑅𝐹𝑆𝐶
𝑎𝑟𝑒𝑎𝐼𝑆
 246 
Equation 2 IS=Internal Standard; SC=Specific Compound of Interest; IRFSC=Internal Response 247 
Factor for Specific Compound of Interest 248 
2.6. Preparation of peripheral blood mononuclear cells  249 
Fasted blood samples were taken from six healthy volunteers aged 60–75 years, in sodium 250 
heparin vacutainer tubes (Greiner Bio-One Limited, Gloucestershire, UK). The study was 251 
conducted according to guidelines laid down in the Declaration of Helsinki 1975, as revised in 252 
1983. All procedures involving human subjects were approved by the Ethics Committee of the 253 
University of Reading. Written informed consent forms was obtained from all subjects. Blood 254 
was layered over an equal volume of lympholyte (Cedarlane Laboratories Limited, Burlington, 255 
Ontario, Canada) and centrifuged at 930 g for 15 min at room temperature. Peripheral blood 256 
mononuclear cells (PBMCs) were harvested from the interface, washed once with PBS and 257 
then resuspended in Roswell Park Memorial Institute (RPMI) 1640 medium (containing 258 
glutamine, Roswell Park Memorial Institute, Autogen Bioclear Ltd., Wiltshire, UK). These 259 
steps were repeated to obtain low contamination levels of erythrocytes. The pellet was 260 
resuspended in RPMI 1640 medium and cell numbers counted using a cell counter (Coulter, 261 
Fullerton, CA, USA) and trypan blue.  262 
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2.7. Viability assays  263 
To determine the appropriate supernatant concentration, PBMC viability, at different 264 
supernatant concentrations was determined using the trypan blue test. PBMC, adjusted to 2×265 
106 cells/ml, incubated in twenty-four-well plates in the presence of RPMI 1640 medium, pure 266 
gut model medium supernatant, SS1V1, SS2V1 and SS3V1 fermentation supernatant from B-267 
GOS and B. coagulans treated vessels, separately for 24 h at 37°C in an air–CO2 (19:1) 268 
atmosphere incubator. The tested supernatant amount of each treatment was 1%, 1.5%, 2%, 269 
3%, 4%, 5% and 10% (v/v) of 2ml (final working volume). At the end of the incubation, cell 270 
numbers were counted using trypan blue test. According to viability results, only 1% (v/v) was 271 
appropriate to use for different treatment supernatants. 272 
2.8. Cytokine stimulation and detection 273 
PBMCs were adjusted to yield 2×106 cells/ml. PBMCs were incubated in twenty-four-well 274 
plates in the presence of 1 mg/ml lipopolysaccharide (LPS; Sigma Aldrich Co. Ltd., Spain), 1% 275 
(v/v) pure gut model medium, 1 mg/ml LPS with 1% (v/v) pure gut medium or 1 mg/ml LPS 276 
with 1% (v/v) supernatants from each steady state vessel of B-GOS and B. coagulans gut 277 
models for 24 h at 37°C in an air–CO2 (19:1) atmosphere. At the end of the incubation, cell 278 
culture supernatants were collected and stored at -20°C for later analysis of cytokine production. 279 
Non-stimulated cultures were used as blank. 280 
The production of IL-1β, IL-6, IL-8, IL-10 and TNF-α were measured using BD™ Cytometric 281 
Bead Array (CBA) Human Soluble Protein Master Buffer Kit (BD Biosciences, Oxford, UK) 282 
and corresponding BD™ Cytometric Bead Array (CBA) Human Flex Set (BD Biosciences, 283 
Oxford, UK) by BD Accuri™ C6 flow cytometer according to the manufacturer’s instructions. 284 
BDTM CBA analysis software FCAP Array v3.0.1 (BD Biosciences, Oxford, UK) was used to 285 
perform data analysis. 286 
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2.9. Statistical analysis 287 
All statistical tests were performed with the use of SPSS version 18 (SPSS Inc, Chicago, IL). 288 
Results are presented as means ± SD.  289 
Changes in specific bacterial groups, SCFA variation and cytokine production were assessed 290 
between the three steady states using a one-way ANOVA. Significant differences were assessed 291 
by post hoc Tukey HSD (Honestly Significant Difference) test. A value of P <0.05 indicates 292 
there was a significant difference. In addition, for cytokine production, differences from LPS 293 
control values were assessed using an independent t test. Furthermore, independent t test was 294 
used to analyse the difference between B. coagulans and B-GOS treatments at SS3. A value of 295 
P <0.05 was used to indicate a significant difference.  296 
3. Results and Discussion 297 
Previous studies using animal models have found a negative impact of high fat diets on 298 
gastrointestinal health; however, the mechanisms are still not clear (de La Serre et al., 2010; 299 
Everard et al., 2013; Fava et al., 2013; Kim et al., 2012; Lam et al., 2012). Therefore an in vitro 300 
gut model combined with an ex-vivo approach has been used to investigate the impact of high 301 
fat mixture, comparing both prebiotics and probiotics, inoculated with faeces from elderly 302 
persons.   303 
3.1. Viability results 304 
After 24h incubation of PBMCs with supernatants, PBMC viability was measured by trypan 305 
blue. Viability was 91% with RPMI 1640 medium, 75% with 1% (v/v) pure gut model medium, 306 
70% and 62% with 1% (v/v) SS1V1 and SS2V1 supernatants, 58% with 1% (v/v) B. cogulans 307 
SS3V1 supernatant, and 60% with 1% (v/v) B-GOS SS3V1 supernatant. Viability at other 308 
concentrations (1.5%, 2%, 3%, 4%, 5% and 10% v/v) was lower than 40%. Differences in 309 
viability may have an impact on cytokine production; therefore 1% (v/v) supernatant was the 310 
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most appropriate choice.  311 
3.2. In vitro effect of fat on bacterial composition, SCFA and cytokine production 312 
In the current study, using an in vitro approach, high fat supplementation was not observed to 313 
lead to significant changes in bacterial composition (Figure 1 and Supplementary 2), cytokines 314 
induced by LPS ex vivo (Figure 2 and Supplementary 3) or organic acids (Figure 3 and 315 
Supplementary 4). The results observed are in contrast to murine studies, where a reduction in 316 
Bacteroides has been observed (Cani et al., 2007a; Cani et al., 2007i; Mozes, Bujnáková, 317 
Sefcíková, & Kmet, 2008; Neyrinck et al., 2011; Patrone et al., 2012). Additionally, a reduction 318 
in bifidobacteria following a high fat diet has previously been observed (Cani et al., 2007a; 319 
Cani et al., 2007i; Druart et al., 2013), however, these findings are not always reproducible. In 320 
the studies, high fat diets had low carbohydrate (Cani et al., 2007a; Cani et al., 2007i; Druart 321 
et al., 2013). Therefore, a decrease in bifidobacteria may stem from reduced carbohydrate 322 
availability in such approaches. In animal models, a high fat diet has also been observed to 323 
upregulate proinflammatory cytokines, such as TNF-α and IL-1β, leading to inflammation and 324 
a dysregulated immune response (Cani et al., 2007a; Cani et al., 2007i; Chen et al., 2011; Kim 325 
et al., 2012; Lam et al., 2012; Neyrinck et al., 2011; Park et al., 2013). However, there are few 326 
studies using human subjects to investigate effects of high fat diets on microbiota composition 327 
and immune parameters. In the human study of Fava et al. (2013), subjects were fed a high 328 
saturated fat diet for 4 weeks (baseline), and then high monounsaturated fat diets for 24 weeks. 329 
High monounsaturated fat diets did not have any significant effect on individual bacterial 330 
numbers compared to baseline. Notably, this study recruited subjects who were at increased 331 
risk of metabolic syndrome (MS) for a high fat diet treatment. It is suggested that the effect of 332 
dietary fat on microbiota composition may be indirectly related to conjugated bile acids (bile 333 
salts). With increasing fat intake, hepatic production and release of bile acids from the 334 
gallbladder to small intestine, and the amount escaping enterohepatic recycling and entering 335 
15 
 
into the gut is increased. Some members of gut microbiota can convert 7 α-dehydroxylate 336 
primary bile acids into secondary bile acids, which are potentially carcinogenic and related to 337 
colon cancer and gastrointestinal diseases (Ou, DeLany, Zhang, Sharma, & O'Keefe, 2012; 338 
Ridlon, Kang, & Hylemon, 2006). These bacteria normally represent a small proportion in the 339 
gut and consist of species belonging to the genus Clostridium (Wells, Williams, Whitehead, 340 
Heuman, & Hylemon, 2003). Because, in the current study, only 2g/5L bile salts were added 341 
to gut model medium and upper gut secretions are not mimicked, which might explain no 342 
significant microbial changes due to fat intake were observed. The combination with other in 343 
vitro gastric and small intestinal models could provide more valuable insights into the 344 
assessment of high fat diet on microbiota changes and immune function in future (Guerra et al., 345 
2012; Payne, Zihler, Chassard, & Lacroix, 2012).  346 
Inflammation induced by a high fat diet may be related to microbiota changes in vivo. It has 347 
been suggested that alterations in the microbiota could lead to increased gut permeability 348 
following a high fat diet by decreasing mRNA expression of tight junction proteins including 349 
zona occludens-1 (Cani et al., 2008; Lam et al., 2012). With impaired gut barrier function these 350 
would lead to increased LPS translocation to plasma, which in turn leads to inflammation 351 
associated with metabolic disorder (Cani et al., 2007a; de La Serre et al., 2010; Kim et al., 352 
2012). Chylomicrons, which transport dietary fat, also have a high affinity with LPS; and then 353 
can carry and move LPS from the gut lumen into the circulatory system (Ghoshal, Witta, Zhong, 354 
de Villiers, & Eckhardt, 2009). In this study, because high fat mixtures did not change the 355 
microbiota composition and their consequent fermentation metabolites, immune markers were 356 
not influenced by high fat mixture fermentation supernatants in vitro. Results indicate that this 357 
high fat does not directly influence microbiota composition or immune response in vitro. 358 
Therefore a high fat diet did not directly serve as growth substrate for most microbiota. 359 
16 
 
3.3. In vitro effect of B-GOS on bacterial composition 360 
B-GOS is a novel trans- galactooligosaccharide mixture, produced by β- galactosidase activity 361 
of Bifidobacterium bifidum NCIMB 41171 on lactose (Tzortzis, Goulas, & Gibson, 2005). 362 
According to Figure 1 and Supplementary 2, B-GOS supplementation with high fat at SS3 led 363 
to significantly increased numbers of lactobacilli/enterococci (p<0.01, ANOVA), 364 
bifidobacteria (p<0.001, ANOVA), Eubacterium rectale – Clostridium coccoides (p<0.05, 365 
ANOVA), Bacillus spp. (p<0.001, ANOVA) and total bacteria (p<0.05, ANOVA) in three 366 
vessels of gut system compared to SS1 and SS2 (p<0.05, ANOVA). In addition, growth of 367 
Clostridium histolyticum group (p<0.001) and Bacteroides–Prevotella spp. (p<0.001, ANOVA) 368 
in the three vessels was also significantly inhibited by B-GOS supplementation with high fat 369 
at SS3 compared to SS1 and SS2. In the current study, under high fat conditions, B-GOS may 370 
confer a positive impact on the aged colon by conferring positive effects on beneficial bacteria 371 
at the expense of potentially negative bacteria. Similar results were also found in murine studies 372 
using fructo-oligosaccharides (Cani et al., 2007i; Respondek et al., 2013) and inulin (Druart et 373 
al., 2013) as prebiotics following a high fat diet. B-GOS has also been shown to confer positive 374 
effects on microbiota composition in healthy elderly persons (Vulevic et al., 2008; Vulevic et 375 
al., 2015) and overweight adults (Vulevic et al., 2013). The results of these human trials are in 376 
agreement with microbial variations in this in vitro study.  377 
3.4. In vitro effect of B. coagulans on bacterial composition  378 
According to Figure 1 and Supplementary 2, B. coagulans supplementation with high fat at 379 
SS3 significantly stimulated the growth of lactobacilli/enterococci in vessel 2 (p=0.013, 380 
ANOVA) and Bacillus spp. in all three vessels (p<0.001, ANOVA) when compared to SS1. B. 381 
coagulans supplementation also significantly decreased numbers of Clostridium histolyticum 382 
group in vessels 1 (p=0.016, ANOVA) and 3 (p=0.021, ANOVA) and numbers of Bacteroides–383 
Prevotella spp. in vessel 1 (p=0.017, ANOVA) when compared to SS1. B. coagulans 384 
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supplementation significantly stimulated the growth of lactobacilli/enterococci in vessels 1 385 
(p=0.025, ANOVA) and 2 (p=0.003, ANOVA) when compared to SS2. Additionally, growth of 386 
bifidobacteria (p<0.05, ANOVA), Eubacterium rectale – Clostridium coccoides (p<0.05, 387 
ANOVA) and Bacillus spp. (p<0.001, ANOVA) were stimulated in all 3 vessels. In addition, 388 
the growth of Clostridium histolyticum group in the 3 vessels was significantly inhibited by B. 389 
coagulans supplementation compared to SS2 (p<0.05, ANOVA).  390 
B. coagulans could exert positive effects in the aged colon by modulating microbiota 391 
composition and organic acid production. Although B. coagulans has not been used to 392 
modulate the impact caused by high fat in previous studies, B. coagulans can modulate the 393 
microbiota with a significant increase in Bacillus spp., C. litsueburense and F. prausnitzii after 394 
28-day supplementation in healthy elderly persons (Nyangale et al., 2014). In addition, 395 
metabolites produced by B. coagulans are beneficial to gastrointestinal health via production 396 
of nutrients such as organic acids, vitamin K2 and some B vitamins including folate and B12 397 
(Jensen et al., 2010). 398 
3.5. In vitro effects of B-GOS and B. coagulans on SCFA and immune markers 399 
Supernatants from PBMCs cultured without gut model fermentation supernatant were used as 400 
controls (+/-). In the absence of LPS, there was no cytokine stimulation, with the exception of 401 
pure gut model medium that significantly stimulated production of IL-1β, IL-6, IL-10 and TNF-402 
α compared to blank (Figure 2 and Supplementary 3). Pure gut model medium did not change 403 
production of IL-1β, IL-6, IL-8, IL-10 and TNF-α induced by LPS (p<0.05, independent t test). 404 
High fat fermentation supernatants had no significant impact on tested cytokines induced by 405 
LPS (Figure 2 and Supplementary 3). Under high fat conditions, either B-GOS or B. coagulans 406 
fermentation supernatants suppressed LPS-induced TNF-α production (p<0.05, independent t 407 
test) and enhanced LPS-induced IL-10 production (p<0.05, independent t-test). In vessel 3, B-408 
GOS significantly increased IL-10 compared to high fat fermentation supernatant (p=0.049, 409 
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ANOVA). In vessels 2 and 3, under high fat condition B-GOS supernatant reduced IL-6 410 
(p<0.05, independent t test) and IL-1β (p<0.05, independent t test) induced by LPS.  411 
Under high fat conditions in vitro, either B-GOS or B. coagulans led to an anti-inflammatory 412 
impact by down-regulating proinflammatory cytokines and enhancing anti-inflammatory 413 
cytokines induced by LPS. The anti-inflammatory impact of B-GOS or B. coagulans have not 414 
been tested before in animal models under high fat conditions. However, in a few murine 415 
studies, some other prebiotics and probiotics may modulate immune responses by upregulating 416 
anti-inflammatory cytokines and down-regulating proinflammatory cytokines (Cani et al., 417 
2007i). This has been the case for fructooligosaccharides, Bifidobacterium longum (Chen et al., 418 
2011), Lactobacillus spp. (Park et al., 2013).  419 
In the current study, the anti-inflammatory impact of prebiotic or probiotics may be related to 420 
fermentation metabolites. In either prebiotic or probiotic supplemented in vitro gut models, 421 
acetate was the predominant fatty acid, followed by butyrate and propionate (Figure 3 and 422 
Supplementary 4). Compared to SS1, B. coagulans with high fat at SS3 stimulated production 423 
of acetate in vessel 3 (p=0.035, ANOVA). Compared to SS2, B. coagulans significantly 424 
stimulated acetate (p<0.05, ANOVA) and butyrate (p<0.05, ANOVA) in all three vessels. 425 
Compared to SS1, B-GOS with high fat at SS3 significantly stimulated the production of 426 
acetate in all three vessels (p<0.01, ANOVA) and butyrate in vessels 2 and 3 (p<0.05, ANOVA). 427 
Compared to SS2, B-GOS supplementation significantly stimulated acetate (p<0.01, ANOVA) 428 
and butyrate (p<0.01, ANOVA) in the three vessels.  429 
TNF-α production induced by stimuli in vitro could be inhibited by SCFAs, especially butyrate 430 
and acetate (Liu et al., 2012; Segain et al., 2000; Usami et al., 2008; Vinolo et al., 2011). 431 
Butyrate could suppress proinflammatory cytokine production by inhibiting LPS-induced 432 
nuclear factor-κB (NF-κB) activation in vitro (Liu et al., 2012; Segain et al., 2000; Usami et al., 433 
2008; Vinolo et al., 2011). Acetate could down-regulate proinflammatory cytokine production 434 
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by lipoxygenase activation without inhibition of NF-κB (Usami et al., 2008). A variation in 435 
TNF-α is in line with SCFA production by B-GOS or B. coagulans under high fat conditions.  436 
Other fermentation metabolites show an inhibitory impact on TNF-α by blocking NF-κB 437 
activation, such as vitamins and unknown fermentation end-products produced by gut 438 
microbiota (van Hylckama Vlieg, Veiga, Zhang, Derrien, & Zhao, 2011), although they were 439 
not determined in the current study.  440 
IL-10 is an important anti-inflammatory cytokine that could counteract the production of 441 
proinflammatory cytokines, such as TNF-α (Cavaglieri et al., 2003; Saemann et al., 2000). In 442 
the current study, up-regulation of IL-10 indicated that prebiotics or probiotics could positively 443 
modulate the immune response in elderly under high fat conditions, which may be associated 444 
with their fermentation end products. A few studies have shown that butyrate and acetate could 445 
increase IL-10 production in vitro (Cavaglieri et al., 2003; Liu et al., 2012; Segain et al., 2000).  446 
IL-6 is mostly considered as a proinflammatory cytokine and proinflammatory activities of IL-447 
6 are mediated by trans-signaling (Scheller, Chalaris, Schmidt-Arras, & Rose-John, 2011). The 448 
inhibitory effect of B-GOS on IL-6 has been seen previously. In the study of Vulevic et al. 449 
(2008), daily intake of 5.5g BiMuno® mixture (2.64g B-GOS) by healthy elderly volunteers 450 
was shown to decrease IL-6 production. 451 
In the current study, under high fat conditions, either B. coagulans or B-GOS could improve 452 
the gut heath and modulate immune markers. However, when comparing B. coagulans and B-453 
GOS supplementations at SS3, B-GOS significantly stimulated the growth of 454 
lactobacilli/enterococci (p<0.01, independent t test), bifidobacteria (p<0.001, independent t test) 455 
and Eubacterium rectale – Clostridium coccoides (p<0.05, independent t test) to a greater 456 
extent than B. coagulans in the three vessels of gut system (p<0.05, independent t test); while 457 
B. coagulans significantly increased numbers of Bacillus spp. in vessels 1 and 2 to a greater 458 
extent than B-GOS (p<0.05, independent t test). In addition, B-GOS led to significantly greater 459 
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stimulation of acetate in all three vessels of gut system (p<0.05, independent t test). Compared 460 
to B. coagulans fermentation supernatant, B-GOS under high fat condition had lower levels of 461 
IL-6 (p<0.05, independent t test). Therefore, the effects of B. coagulans could be much 462 
enhanced and protected by mixed with prebiotics. The impacts of B. coagulans have been 463 
shown to be enhanced with the addition of potentially prebiotic β-glucans (Arena et al., 2016) 464 
and inulin (Abhari, Shekarforoush, Sajedianfard, Hosseinzadeh, & Nazifi, 2015). The anti-465 
inflammatory impacts can be enhanced by synergistic effects of combination of B. coagulans 466 
and β-glucans (Arena et al., 2016). Inulin could enhance the survival and growth of B. 467 
coagulans, with the number of spores significantly higher in synbiotic fed rats compared to 468 
probiotic fed (Abhari et al., 2015).  469 
In conclusion, high fat addition did not significantly influence the composition of bacteria and 470 
immune responses in vitro. However under high fat conditions, either B. coagulans or B-GOS 471 
may act as health-promoting food supplements to enhance the aged gastrointestinal tract by 472 
targeting specific bacterial groups, increasing saccharolytic fermentation and modulating 473 
immune markers. Human intervention research would further clarify pre/probiotic effects 474 
during high fat diets on elderly gut microbiota and mechanisms of microbial and immune 475 
response modulation. 476 
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Table 1 Feeding materials added to three-stage continuous culture daily at stage SS2 and 697 
SS3 698 
 
 
Amount (daily)  
SS2-high fat treatment Unsalted butter  2g 
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Sunflower oil  1.17g 
Olive oil  1.33g 
Coconut oil  0.83g 
SS3-high fat and prebiotic treatment* 
glucose 0.394g 
galactose 0.017g 
lactose 0.348g 
B-GOS  1.063g 
Protein  0.003g 
Ash  0.008g 
Moisture  0.661g 
SS3-high fat and probiotic 
treatment*  
B. coagulans  3.3×108 cfu 
At stage SS3, same amount of high fat treatment were added to culture daily as SS2. The same 699 
amounts of glucose, galactose and lactose were also added to non-prebiotic fed culture daily.   700 
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Table 2 Hybridisation and washing conditions for oligonucleotide probes 
Probe name Sequence (5’ to 3’) Hybridisation 
pre-treatment 
Formamide (%) in 
hybridisation 
buffer 
Hybridisation-
washing temperature 
(°C) 
Reference  
Ato 291 GGTCGGTCTCTCAACCC Lysozyme 0 50-50 (Harmsen et al., 2000) 
Lab 158 GGTATTAGCAYCTGTTTCCA Lysozyme 0 50-50 (Harmsen et al., 1999) 
Bif 164 CATCCGGCATTACCACCC Lysozyme 0 50-50 (Langendijk et al., 1995) 
Erec 482 GCTTCTTAGTCARGTACCG None  0 50-50 (Franks et al., 1998) 
Chis 150 TTATGCGGTATTAATCTYCCTTT None 0 50-50 (Franks et al., 1998) 
Bcoa 191 GCCGCCTTTCCTTTTTCCTCC Lysozyme 20 46-48 (Sakai & Ezaki, 2006) 
Bac 303 CCAATGTGGGGGACCTT None  0 46-48 (Manz et al., 1996) 
EUB338* GCTGCCTCCCGTAGGAGT None 35 46-48 (Daims et al., 1999) 
EUB338II* GCAGCCACCCGTAGGTGT None 35 46-48 (Daims et al., 1999) 
EUB338III* GCTGCCACCCGTAGGTGT None 35 46-48 (Daims et al., 1999) 
* These probes were used together in equimolar concentrations (all at 50 ng l1) 
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Table 3 Bacterial numbers in three different vessels (Vessel 1, Vessel 2, Vessel 3) of in vitro 
colonic models before adding any treatment at steady state (SS) 1, after adding high fat 
mixture at SS2, and after adding high fat mixture with B-GOS/ B. coagulans treatment at 
SS3. 
  B-GOS B. coagulans 
Group   Vessel 1 Vessel 2 Vessel 3 Vessel 1 Vessel 2 Vessel 3 
Log10 bacteria number/ml 
Lab 158  SS1 8.69± 0.10a 8.43± 0.14a 8.11± 0.12a 8.71± 0.06ab 8.38± 0.07a 8.12± 0.11 
SS2 8.56± 0.14a 8.33± 0.09a 8.04± 0.12a 8.57± 0.08a 8.32± 0.02a 8.07± 0.09 
SS3 9.21± 0.08b* 9.03± 0.05b* 8.79± 0.09b* 8.81± 0.06b* 8.58± 0.04b* 8.24± 0.06* 
Bif 164  SS1 8.76± 0.12a 8.68± 0.15a 8.51± 0.13a 8.83± 0.08ab 8.72± 0.14ab 8.53± 0.07ab 
SS2 8.63± 0.13a 8.55± 0.09a 8.39± 0.08a 8.67± 0.07a 8.52± 0.09a 8.35± 0.06a 
SS3 9.91± 0.05b* 9.80± 0.04b* 9.69± 0.04b* 9.05± 0.09b* 8.85± 0.06b* 8.67± 0.11b* 
Erec 482  SS1 9.38± 0.06a 9.23± 0.07a 9.13± 0.07a 9.43± 0.03ab 9.32± 0.08ab 9.15± 0.05ab 
SS2 9.12± 0.15a 8.91± 0.11a 8.73± 0.05a 9.13± 0.15a 8.90± 0.10a 8.68± 0.06a 
SS3 9.72± 0.06b* 9.57± 0.09b* 9.47± 0.08b* 9.49± 0.05b* 9.22± 0.07b* 9.12± 0.07b* 
Chis 150  SS1 7.35± 0.08b 7.20± 0.06b 6.63± 0.07b 7.25± 0.03b 6.99± 0.19ab 6.54± 0.05b 
SS2 7.41± 0.06b 7.35± 0.09b 7.03± 0.15b 7.42± 0.09b 7.36± 0.11b 6.99± 0.11b 
SS3 6.47± 0.09a* 6.35± 0.09a* 6.13± 0.06a 6.91± 0.10a* 6.83± 0.04a* 6.36± 0.10a 
Bcoa 191  SS1 7.00± 0.01a 6.71± 0.10a 6.61± 0.08a 7.01± 0.02a 6.77± 0.04a 6.64± 0.09a 
SS2 6.90± 0.02a 6.65± 0.08a 6.55± 0.07a 7.04± 0.04a 6.73± 0.05a 6.58± 0.02a 
SS3 7.43± 0.06b* 7.34± 0.07b* 7.22± 0.09b 7.90± 0.01b* 7.69± 0.12b* 7.34± 0.07b 
Bac 303  SS1 9.48± 0.02b 9.13± 0.07b 8.80± 0.01b 9.46± 0.04b 9.12± 0.07 8.77± 0.03 
SS2 9.38± 0.05b 8.86± 0.04b 8.64± 0.08b 9.41± 0.04ab 8.95± 0.06 8.75± 0.11 
SS3 8.79± 0.09a* 8.14± 0.08a* 7.96± 0.13a* 9.08± 0.09a* 8.39± 0.02* 8.28± 0.02* 
Ato 291  SS1 8.85± 0.10 8.43± 0.06 8.20± 0.17 8.88± 0.04 8.50± 0.18 8.20± 0.23 
SS2 8.75± 0.10 8.38± 0.08 8.07± 0.18 8.73± 0.10 8.39± 0.15 8.18± 0.17 
SS3 9.01± 0.13 8.74± 0.32 8.48± 0.28 8.86± 0.09 8.50± 0.17 8.23± 0.20 
EUB 338  
mixture 
SS1 10.06± 0.03a 10.01± 0.08a 9.82± 0.08a 10.03± 0.06 9.96± 0.05 9.64± 0.08 
SS2 10.00± 0.08a 9.88± 0.04a 9.69± 0.08a 10.04± 0.05 9.98± 0.09 9.60± 0.13 
SS3 10.26± 0.02b 10.18± 0.03b 10.08± 0.05b* 10.20± 0.06 10.13± 0.04 9.77± 0.05* 
Values are based on the average of six gut models using faeces from three elderly subjects± SD. 
Results are calculated based on the means of data from three consecutive days in each vessel 
and each steady state.  
Lab 158 - lactobacilli/enterococci, Bif 164 - bifidobacteria, Erec 482 - Eubacterium rectale – 
Clostridium coccoides, Chis 150 - the Clostridium histolyticum, Bcoa 191 - Bacillus spp., Bac 
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303 - Bacteroides–Prevotella spp., Ato 291 - Atopobium, and EUB 338 mixture - total bacteria. 
* Significance difference between B. coagulans and B-GOS treatment at SS3, p<0.05. 
Significant differences (p<0.05) among SS1, SS2 and SS3. in the same vessel are indicated with 
different letters. 
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Table 4 Short chain fatty acids concentration analysed by GC for three different vessels (Vessel 1, Vessel 2, Vessel 3) of in vitro colonic 
models before adding any treatment at steady state (SS) 1, after adding high fat mixture at SS2, and after adding high fat mixture with B-
GOS/ B. coagulans treatment at SS3. 
 Acetic acid Propionic acid Butyric acid Iso-butyric acid Iso-valeric acid 
 vessel 1 vessel 2 vessel 3 vessel 1 vessel 2 vessel 3 vessel 1 vessel 2 vessel 3 vessel 1 vessel 2 vessel 3 vessel 1 vessel 2 vessel 3 
B-GOS 
SS1 59.43± 70.42± 74.46± 31.38± 36.99± 39.39± 36.00± 40.76± 43.15± 0.88± 2.77± 3.37± 1.06± 3.04± 3.60± 
5.57a 3.95a 5.50a 2.66b 3.47b 3.32b 4.70ab 4.16a 5.31a 0.34b 0.40b 0.21b 0.37b 0.16b 0.26b 
SS2 51.46± 63.78± 68.46± 26.17± 32.38± 35.85± 25.19± 29.83± 31.99± 0.66± 2.58± 2.99± 0.86± 2.42± 3.20± 
5.22a 5.21a 6.03a 2.43ab 2.40ab 3.77ab 6.22a 4.91a 4.71a 0.15ab 0.33ab 0.05ab 0.34ab 0.22b 0.32b 
SS3 86.51± 102.35
± 
106.70
± 
18.73± 23.92± 27.37± 48.30± 52.84± 57.96± 0.10± 1.45± 1.74± 0.08± 1.33± 1.93± 
4.44b* 6.75b* 6.32b* 3.16a 2.96a 2.58a 2.31b 2.09b* 3.39b* 0.02a 0.39a 0.42a 0.01a* 0.36a 0.48a 
B. coagulans 
SS1 56.76± 65.42± 70.62± 29.05± 34.71± 38.54± 35.78± 40.24± 41.75± 0.78± 3.08± 3.38± 1.25± 3.00± 3.49± 
4.50ab 4.72ab 4.45a 3.21 3.82 4.21 6.18ab 3.78ab 3.32ab 0.22b 0.19b 0.30b 0.22b 0.17b 0.23b 
SS2 48.24± 61.52± 65.12± 23.65± 28.74± 30.82± 24.57± 30.33± 32.73± 0.71± 2.78± 3.22± 1.12± 2.87± 3.33± 
3.84a 6.04a 4.88a 2.94 1.50 1.93 4.23a 3.27a 3.94a 0.20ab 0.37b 0.27ab 0.24b 0.10b 0.26b 
SS3 64.04± 79.08± 87.58± 27.71± 32.85± 37.69± 40.02± 42.70± 44.44± 0.19± 1.54± 2.45± 0.44± 1.95± 2.14± 
4.31b* 4.99b* 5.72b* 4.67 4.06 5.71 4.28b 2.65b* 3.26b* 0.12a 0.38a 0.30a 0.17a* 0.17a 0.21a 
Values are based on the average of six gut models from three elderly subjects and reported as mM ± SD. Results from each gut model are calculated 
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based on the means of data from three consecutive days in each vessel and each steady state. * Significance difference between B. coagulans and 
B-GOS treatment at SS3, p<0.05. Significant differences (p<0.05) among SS1, SS2 and SS3 in the same vessel are indicated with different letters. 
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Figure 1 Effect of fermentation supernatants from three different vessels (Vessel 1, Vessel 
2, Vessel 3) of in vitro colonic models before adding any treatment at steady state (SS) 1, 
after adding high fat mixture at SS2, and after adding high fat mixture with B-GOS/ B. 
coagulans treatment at SS3 on microbiota composition. Values are mean ± SD. * 
Significance difference between B. coagulans and B-GOS treatment at SS3, p<0.05. Significant 
differences (p<0.05) among SS1, SS2 and SS3 from same treatment are indicated with different 
letter. 
Figure 2 Effect of fermentation supernatants from three different vessels (Vessel 1, Vessel 
2, Vessel 3) of in vitro colonic models before adding any treatment at steady state (SS) 1, 
after adding high fat mixture at SS2, and after adding high fat mixture with B-GOS/ B. 
coagulans treatment at SS3 on cytokine production by peripheral blood mononuclear cells 
(PBMC). Values are mean ± SD. #, significant differences from LPS value p<0.05. *, 
significance difference between B. coagulans and B-GOS treatment at SS3, p<0.05. Significant 
differences (p<0.05) among SS1 (no fat and treatment), SS2 (high fat mixture addition) and 
SS3 (high fat mixture with B. coagulans/B-GOS treatment) in the same vessel were indicated 
with different letters. Supernatants from PBMCs cultured without gut model supernatant were 
used as controls (+/-). In addition, cytokines in non-stimulated PBMC (blank) and in only pure 
gut model medium-treated PBMC (gut) were also determined. There were significant 
differences between them in cytokines IL-1β, IL-6, IL-10 and TNF-α (not presented in figures). 
There was also no significant difference between LPS (LPS-stimulated PBMC) and gut+LPS 
(PBMC incubated with pure gut model medium and LPS).  
Figure 3 Effect of fermentation supernatants from three different vessels (Vessel 1, Vessel 
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2, Vessel 3) of in vitro colonic models before adding any treatment at steady state (SS) 1, 
after adding high fat mixture at SS2, and after adding high fat mixture with B-GOS/ B. 
coagulans treatment at SS3 on SCFA. Values are mean ± SD. * Significance difference 
between B. coagulans and B-GOS treatment at SS3, p<0.05. Significant differences (p<0.05) 
among SS1, SS2 and SS3 from same treatment are indicated with different letter. 
Supplementary Figure 2 Effect of fermentation supernatants from three different vessels 
(Vessel 1, Vessel 2, Vessel 3) of in vitro colonic models before adding any treatment at 
steady state (SS) 1, after adding high fat mixture at SS2, and after adding high fat mixture 
with B-GOS/ B. coagulans treatment at SS3 on microbiota composition. Values are mean ± 
SD. * Significance difference between B. coagulans and B-GOS treatment at SS3, p<0.05. 
Significant differences (p<0.05) among SS1, SS2 and SS3 from same treatment are indicated 
with different letter. 
Supplementary Figure 3 Effect of fermentation supernatants from three different vessels 
(Vessel 1, Vessel 2, Vessel 3) of in vitro colonic models before adding any treatment at 
steady state (SS) 1, after adding high fat mixture at SS2, and after adding high fat mixture 
with B-GOS/ B. coagulans treatment at SS3 on cytokine production by peripheral blood 
mononuclear cells (PBMC). Values are mean ± SD. #, significant differences from LPS value 
p<0.05. *, significance difference between B. coagulans and B-GOS treatment at SS3, p<0.05. 
Significant differences (p<0.05) among SS1 (no fat and treatment), SS2 (high fat mixture 
addition) and SS3 (high fat mixture with B. coagulans/B-GOS treatment) in the same vessel 
were indicated with different letters. Supernatants from PBMCs cultured without gut model 
supernatant were used as controls (+/-). In addition, cytokines in non-stimulated PBMC (blank) 
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and in only pure gut model medium-treated PBMC (gut) were also determined. There was also 
no significant difference between LPS (LPS-stimulated PBMC) and gut+LPS (PBMC 
incubated with pure gut model medium and LPS). 
Supplementary Figure 4 Effect of fermentation supernatants from three different vessels 
(Vessel 1, Vessel 2, Vessel 3) of in vitro colonic models before adding any treatment at 
steady state (SS) 1, after adding high fat mixture at SS2, and after adding high fat mixture 
with B-GOS/ B. coagulans treatment at SS3 on SCFA. Values are mean ± SD. * Significance 
difference between B. coagulans and B-GOS treatment at SS3, p<0.05. Significant differences 
(p<0.05) among SS1, SS2 and SS3 from same treatment are indicated with different letter. 
  
 
 
 
 
